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Abstract
Our aim was to determine the characteristics, treatments and outcomes of patients with pri-
mary spinal glioblastomas (GB) or gliosarcomas (GS) reported in literature until March
2015. PubMed andWeb of Science were searched for peer-reviewed articles pertaining to
cases of glioblastomas / gliosarcomas with primary spinal origin, using predefined search
terms. Furthermore we performed hand searches tracking the references from the selected
papers. Eighty-two articles published between 1938 and March 2015 were eligible. They
reported on 157 patients. Median age at diagnosis was 22 years. The proportion of patients
who received adjuvant chemo- or radiotherapy clearly increased from the time before 1980
until present. Median overall survival from diagnosis was 8.0 ± 0.9 months. On univariate
analysis age influenced overall survival, whereas tumor location, gender and the extent of
initial resection did not. Outcomes did not differ between children (< 18 years) and adults.
However, the patients who were treated after 1980 achieved longer survival times than the
patients treated before. On multivariable analysis only age (< 60 years) and the time period
of treatment ( 1980) were confirmed as positive independent prognostic factors. In conclu-
sion, primary spinal GB / GS mainly affect younger patients and are associated with a dis-
mal prognosis. However, most likely due to the increasing use of adjuvant treatment,
modest therapeutic progress has been achieved over recent decades. The characteristics
and treatments of primary spinal glioblastomas should be entered into a central registry in
order to gain more information about the ideal treatment approach in the future.
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Introduction
In adults, glioblastoma (GB) is the most frequent primary intracranial neoplasm accounting
for more than 50% of all cerebral tumors [1]. In contrast, pediatric GB are rare. Data on child-
hood malignancies from the European Union show that only 3% of all children with central
nervous system (CNS) tumors are affected by this disease [2]. Both -in adults and children- spi-
nal origin of glioblastoma is rarely seen and accordingly, the literature on the topic is mainly
restricted to single case reports or small case series. It is noteworthy that there are crucial differ-
ences between adult and pediatric malignant gliomas in terms of tumor biology and clinical
course, implying that the results from adult clinical trials may not be extrapolated to children
and vice versa [3]. Beyond their dismal prognosis, little is known about the clinical characteris-
tics of primary spinal glioblastomas / gliosarcomas and their optimal treatment. By means of a
systematic review referring to 157 cases of primary spinal GB / GS which were published in lit-
erature until March 2015, this paper updates and summarizes the existing knowledge on this
rare disease.
Materials and Methods
Aim of the study
The primary objective of this study was to assess clinical characteristics, treatments and out-
comes of GB / GS patients with primary spinal tumor location. Our aim was to include all cases
reported in literature until March 2015. The secondary objective was to evaluate potential
prognostic factors for survival.
Search strategy and selection criteria
Identification. In a first step we performed PubMed andWeb of Science searches with
predefined search terms (for details see S1 Search Methods). We restricted our search to articles
written in German, French, Spanish, Italian or English, but did not use any time limitations. In
total, the search engines delivered 1509 hits, which were imported into a reference manage-
ment software (endnote.com X6.0.1). After removal of duplicates, the number of hits was
reduced to 1211.
Screening. Titles and abstracts were reviewed by two authors (SB and KM). The minimum
requirement for further consideration of a case was the diagnosis of a primary spinal GB / GS,
as well as information on the patient´s treatment and the course of disease.
Application of these basic inclusion criteria excluded 1126 publications after title screening
and nine after abstract screening. Hand searches tracking the references from the 76 remaining
articles revealed 21 further publications, which were added to the pool of papers meriting closer
investigation (n = 97).
Eligibility. In total, we (SB and KM) evaluated 97 full-text articles for eligibility. Disagree-
ments were resolved through discussion and consensus with a third author (SP). Fifteen articles
had to be excluded because they did not fulfill the other aforementioned inclusion criteria. In
total, we included 82 articles published between 1938 and 2015 and reporting on a total of 157
patients. Apart from one pilot study, all articles were case reports or small retrospective case
series. The pilot study of the Children’s Cancer Group (CCG), CCG-945, enrolled 18 patients
with newly diagnosed primary spinal high-grade astrocytomas, including four children with
glioblastoma multiforme [4]. All case series focused on malignant spinal cord tumors with a
maximum of 14 glioblastoma cases. The procedure of publication retrieval and in- and exclu-
sion of cases is displayed in a PRISMA (Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) flow chart (Fig 1) [5].
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Data extraction. From the eligible articles, the following variables were recorded on a
standard data extraction form:
(1). Overall survival
(2). Pattern of failure (local versus distant)
(3). year of publication
(4). age at initial diagnosis
(5). gender
(6). histology
(7). site of primary tumor, compiled into
a. cervical spinal cord
b. cervicothoracic spinal cord
c. thoracic spinal cord
d. thoracolumbar spinal cord
e. lumbar spinal cord
f. cervicolumbar spinal cord / holocord
(9). treatment after diagnosis, categorized as
a. not reported or best supportive care
b. surgery only
c. chemotherapy only
d. radiotherapy only
Fig 1. Procedure of publication retrieval and in- and exclusion of cases displayed in a PRISMA
(Preferred Reporting Items for Systematic Reviews andMeta-Analyses) flow chart (4).
doi:10.1371/journal.pone.0148312.g001
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e. radiotherapy + chemotherapy
f. surgery + radiotherapy
g. surgery + chemotherapy
h. surgery + chemotherapy + radiotherapy
Statistics
The follow-up time of the patients was quantified according to the method suggested by
Schemper and Smith [6]. Survival times were calculated from the time of diagnosis of primary
spinal GB / GS. Death resulting from any cause was defined as event for overall survival (OS).
The Kaplan-Meier method was used to estimate OS. Figures were rounded to the nearest inte-
ger whenever appropriate.
Univariate analysis. OS was estimated using the Kaplan-Meier method. Survival plots
relating to categorical variables were compared by means of the log rank test. A difference was
assumed if the p-value was less than 0.05.
Multivariable analysis. In addition, a multivariable cox proportional hazards analysis
including the four categorical variables age at diagnosis (cutoff 60 years), time period of publi-
cation (cutoff 1980), tumor location (involvement of the cervical spinal cord, yes or no) and
extent of resection (gross total resection (GTR), yes or no) was performed using a forward step-
wise selection; predictors were removed when their p-value in the likelihood ratio-test was
greater than 0.10. Proportional hazards assumptions were checked graphically. For the final
models, the estimated hazard ratios of the selected explanatory variables with respective 95%
confidence intervals (CI) and p-values of the likelihood ratio test are given. A value of p< 0.05
was considered statistically significant. All analyses were conducted using SPSS, version 20.0
(SPSS Inc., Chicago, IL, USA).
Results
Clinical Characteristics
Gender was unknown in 2/157 cases (1%). 84/155 patients (54%) were male and 71/155 (46%)
female. Median follow-up time was 96 ± 43 months. The 95% confidence interval of the
median follow-up time reached from 13 to 179 months. Age at initial diagnosis was reported
for all patients. Median age at initial diagnosis was 22 years (range 0–88 years) (Fig 2). Histo-
pathological diagnosis revealed GB in 155/157 cases (99%). Two patients (1%) had GS. Sixty-
six patients (42%) were children or adolescents (< 18 years). Only 10 patients (6%) were 60
years old or older. The tumors affected the cervical spinal cord in 75/157 cases (48%). In 14/
157 cases (9%) the patients received best supportive care only. In the remaining 143/157 cases
(91%) more intensive treatments were applied. Nineteen patients (13%) underwent surgery
only, fourteen patients (10%) received exclusively radiotherapy and one patient (1%) was
treated with no more than chemotherapy. 109 (76%) patients underwent a combination of dif-
ferent treatments (surgery + chemotherapy, n = 4; surgery + radiotherapy, n = 47; chemother-
apy + radiotherapy, n = 15; surgery + chemotherapy + radiotherapy, n = 43). In 5/157 cases
(3%) it remained unclear whether initial GTR was achieved or not. 36 of the remaining 152
patients (24%) underwent initial GTR, whereas 116 (76%) did not. The proportion of patients
in whom GTR was initially achieved remained relatively constant over decades (before 1980, 4/
21 patients (19%); between 1980 and 2015, 32/131 patients (24%)). In 8/157 cases (5%) it
remained unclear whether adjuvant radiotherapy was given or not. 119 of the remaining 149
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patients (80%) underwent irradiation, whereas 30 (20%) did not. The proportion of irradiated
patients continued to increase over the decades (before 1980, 14/23 patients (61%); between
1980 and 2015, 105/126 patients (83%)). In 31/157 cases (20%) it remained unclear whether
adjuvant chemotherapy was given or not. Only half of the remaining 126 patients (n = 63
patients, 50%) received chemotherapy. The proportion of patients who received chemotherapy
continued to increase over the decades (before 1980, 1/23 patients (4%); between 1980 and
2015, 62/103 patients (60%)). The total radiation doses ranges from 18 Gy to 75 Gy with an
average value of 49.2 Gy. In total 63 patients received chemotherapy (Table 1). The most fre-
quent chemotherapeutic agent was temozolomide, it was used in 30/63 cases (48%). The sec-
ond most commonly used drug was the angiogenesis inhibitor bevacizumab, which was
prescribed in 11/63 cases (18%).
Overall survival from initial diagnosis. In 130/157 cases sufficient information was avail-
able to estimate overall survival from initial diagnosis (OS). Median OS of these 130 patients
was 9.0 ± 0.8 months. Only 15% ± 3% of the patients were still alive two years after the initial
diagnosis (Fig 3).
Potential prognostic factors for overall survival
Univariate analysis using the Kaplan Meier method and log rank test. On univariate
analysis age at initial diagnosis and the time period when the medical treatment was performed
influenced OS. Advanced age was related to a worse prognosis. Patients younger than 60 years
of age had a median overall survival of 10.0 ± 0.8 months, whereas it was only 1.0 ± 0.5 months
in the 60-plus cohort (p< 0.0001) (Fig 4). A similar effect was observed when using 50 years as
cut-off (p = 0.043). In contrast, children (< 18 years) and adults ( 18 years) showed compara-
ble outcomes (p = 0.398). Patients treated before 1980 had shorter survival times (median OS,
5.0 ± 0.7 months) than patients treated between 1980 and 2015 (median OS, 10.0 ± 1.0 months,
p = 0.012) (Fig 5). In contrast, OS was not influenced by initial gross total resection (GTR)
(p = 0.094), gender (p = 0.311) or cervical spinal cord affection (p = 0.057) (Table 2).
Fig 2. Age distribution of 157 patients with primary spinal origin reported in literature until March
2015. It is displayed in the form of a histogram. Median age at diagnosis was 22 years.
doi:10.1371/journal.pone.0148312.g002
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Multivariable analysis using cox regression. Multivariable analysis only identified age at
diagnosis< 60 years (hazard ratio = 0.097, 95% CI: 0.043–0.217, p< 0.0001) and the time
period of publication (< 1980, hazard ratio 1.996, 95% CI: 1.182–3.372, p = 0.010) as indepen-
dent predictors of survival. In contrast, the extent of resection (GTR) and tumor location (cer-
vical affection) did not reach statistical significance.
Table 1. Clinical characteristics and treatments of 157 patients with primary spinal GB / GS reported
in literature until March 2015.
total %
Gender not speciﬁed 2/157 1
Male 84/155 54
Female 71/155 46
Children (< 18 years) 57/157 36
Adults (> = 18 years) 100/157 64
GBM 155/157 99
GS 2/157 1
Surgery only 19/143 13
Radiotherapy only 14/143 10
Chemotherapy only 1/143 1
Combination of different treatments 109/143 76
Surgery + chemotherapy 4/109 4
Surgery + radiotherapy 47/109 43
Chemotherapy + radiotherapy 15/109 14
Surgery + chemotherapy + radiotherapy 43/109 39
Supportive care only 14/157 9
Death 130/157 83
GB: Glioblastoma, GS: Gliosarcoma
doi:10.1371/journal.pone.0148312.t001
Fig 3. Overall survival of 130 patients with primary spinal glioblastomas /- sarcomas reported in
literature until March 2015. In 27 of the 157 patients (17%) survival data were not available.
doi:10.1371/journal.pone.0148312.g003
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Discussion
General aspects
In adults, glioblastoma is the most frequent malignant brain tumor. Metastases to the spinal
cord or primary spinal location are rare. In two previous meta-analyses we focused on patients
with metastatic disease [7, 8]. Now, we generated a large database of glioblastoma cases with
primary spinal location. 157 patients reported in the literature until March 2015 met our inclu-
sion criteria and were evaluated in detail. We focused our analysis on patient characteristics,
treatments, prognosis and factors associated with survival.
A similar population-based analysis using data from the population-based cancer registries
of the Surveillance, Epidemiology and End Results (SEER) program from 1973–2007 had
already been published in 2012. However, the authors, Adams et al., did not exclusively focus
on glioblastomas (WHO grade IV) but also included spinal anaplastic astrocytomas (WHO
grade III) into their study. Moreover, the number of glioblastoma cases was much smaller
(n = 59) [9].
Which age group is at risk for primary spinal glioblastoma?
Interestingly, our data suggest that primary spinal glioblastomas / -sarcomas mainly affect
younger patients. Median age at diagnosis in our cohort was 22 years. Only 10/157 patients
(6%) were 60 years old or older. This result matches well with the findings of Adams et al. who
calculated a mean age of 35 years in their cohort [9]. In contrast, the median age of patients
with primary intracranial glioblastomas is much higher. For example in our previous meta-
analyses, the median age at initial diagnosis was 42 years [7] and 44 years [8]. Furthermore, in
the well known European cohort evaluated by Stupp et al. in order to demonstrate the benefit
of temozolomide, the median age at diagnosis was 56 years [10]. Older data from the Los Ange-
les County Cancer Surveillance Program showed an even higher median age at diagnosis of
intracranial glioblastoma at approximately 65 years [11].
Fig 4. Impact of age on overall survival (OS).On univariate analysis the older patients ( 60 years at initial
diagnosis) had significantly shorter survival times (p < 0.0001).
doi:10.1371/journal.pone.0148312.g004
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What is the prognosis of patients with primary spinal glioblastomas?
In the 1980s high-grade gliomas of spinal origin were thought to have the same outcome as
their intracranial counterparts [12]. However, the prognosis of the latter has significantly
improved over the past decades and the question arises whether this statement is still true.
Depending on tumor biology, particularly on the methylation status of the O6-methylguanine-
DNAmethyltransferase (MGMT) promotor, intracranial glioblastomas are now characterized
Fig 5. Overall survival (OS) according to the publications before and after 1980. Amodest increase in
treatment success has been achieved over recent decades.
doi:10.1371/journal.pone.0148312.g005
Table 2. Evaluation of potential risk factors for overall survival using Kaplan Meier method and log rank test.
Subgroup Number of patients Deaths Median OS (months) SE Log rank p =
male 70 65 8.0 1.5 0.311
female 58 57 10.0 0.9 0.311
< 18 years at ID 57 54 9.0 1.5 0.398
> = 18 years at ID 73 70 9.0 1.3 0.398
< 50 years at ID 108 102 10.0 1.0 0.043
> = 50 years at ID 22 22 3.0 0.7 0.043
< 60 years at ID 122 116 10.0 0.8 < 0.0001
> = 60 years at ID 8 8 1.0 0.5 < 0.0001
Initial GTR 34 30 12.0 2.5 0.094
no GTR 93 91 8.0 1.1 0.094
cervical affection 65 63 8.0 1.4 0.057
no cervical affection 65 61 10.0 1.2 0.057
time period of treatment
before 1980 19 18 5.0 0.7 0.012
1980–2015 111 106 10.0 1.0 0.012
OS: overall survival, SE: standard error, ID: initial diagnosis, GTR: gross total resection
doi:10.1371/journal.pone.0148312.t002
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by median survival rates ranging between 15 and 22 months when patients are treated with an
up-to-date multidisciplinary approach. This consists of surgical resection and radiotherapy (60
Gy) combined with concomitant and adjuvant treatment with temozolomide [13]. According
to this, in a recent article, the estimated „average survival”of patients with spinal glioblastomas
was 18 months [14]. However, an explanation of how this figure was calculated was not
provided.
In contrast, median survival in our cohort was clearly worse (9.0 ± 0.8 months). Only
15 ± 3% of patients were still alive two years after the initial diagnosis. In the analyses of
Adams et al. [9] and Santi et al. [15] the median survival of patients with spinal glioblastomas
was 10 months which is in line with our findings. Even when focusing on the cases which were
reported after 2005, i.e. on the patients, who should have been treated in accordance with mod-
ern treatment principles, median survival in our cohort is still remarkably poor (11.0 ± 1.1
months).
Which factors impact on survival?
In the analysis of Adams et al. only the histological subtype, age at diagnosis (particularly when
categorizing the patients into children and adults), sex, and the extent of resection were associ-
ated with survival in a final multivariable model. Of note, this cohort mainly contained patients
with primary spinal anaplastic astrocytomas, whereas the number of GB patients was limited
(n = 59) [9]. Focusing on WHO grade IV tumors and based on a considerably larger number of
cases (n = 157) the present analysis paints a partially different picture.
In contrast to the findings of Adams et al. [9] female gender was not related to poorer
survival. Our result is supported by a landmark study on prognostic factors in malignant
glioma patients with an intracranial tumor site. The authors, Curran et al., assessed a total
of 1578 patients entered in three consecutive Radiation Therapy Oncology Group malig-
nant glioma trials and developed a prognostic model in which gender did not have any rele-
vance [16].
The question whether radical resection is beneficial for the outcome of patients with spinal
malignant gliomas is controversial. In the present study the patients with initial gross total
resection (GTR) did not show longer survival. In contrast, the data from the SEER database
showed a significant association of the extent of surgical resection with survival in both uni-
and multivariable analyses [9]. However, a previous smaller series failed to demonstrate an
impact of radical resection on survival [17]. In an Italian study surgical treatment did not ame-
liorate the neurological status; instead, in the majority of cases, it prompted a worsening of the
deficits [18]. In the setting of a pre-existing tumor-related complete neurological deficit cor-
dectomy may be a valuable therapeutic alternative. Nevertheless, this radical approach is only
feasible if the upper thoracic and cervical spinal cord are intact. Some authors suppose that cor-
dectomy may provide longer survival than would otherwise be achievable with more radiation
or the addition of chemotherapy [14]. In our series we identified 6 patients undergoing cor-
dectomy. Indeed, all but one [19] showed excellent survival rates ranging between 14 and 144
months [20–22, 14].
In our study children and adults with primary spinal GB / GS shared the same outcomes
whereas the analysis of Adams et al. demonstrated a difference between the pediatric and adult
age groups and their survival rates. Here, the median survival of adult patients in comparison
to the pediatric cohort was significantly better at 16 versus 9 months [9]. Due to these contra-
dicting study results the question whether pediatric and adult tumors are characterized by dif-
ferent prognoses remains unanswered. In two previous studies of our working group focusing
on metastatic GB / GS we encountered the same problem [7, 8].
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Of note, in the present analysis age (as categorical variable) became a powerful prognostic
factor in both uni- and multivariable analysis when assessing a different cut-off. On univariate
analysis the median overall survival of patients younger than 60 years of age was ten times lon-
ger than that of the 60-plus cohort. A similar effect was observed with a cut-off of 50 years.
These findings are very plausible as in the setting of primary intracranial disease old age was
already identified as one of the pretreatment variables most predictive of survival outcome
some decades ago [16].
In the present analysis, the second independent prognostic factor for survival was the time
period in which the patients underwent treatment. In univariate analysis, the patients treated
before 1980 had shorter survival times than the patients treated between 1980 and 2015,
respectively. A possible explanation for this may be that the use of adjuvant treatment (radio-
and chemotherapy) significantly increased from the time before 1980 until present. Of note,
this explanation is highly speculative as prospective studies demonstrating the benefit of adju-
vant radiotherapy in spinal cord malignant gliomas are absent [23, 24, 9]. Based on an older
retrospective analysis Shirato et al. recommended conventional radiotherapy after less than
total resection of spinal cord astrocytomas [25]. However, their conclusions have to be treated
with caution since they treated very low patient numbers.
To the best of our knowledge the same applies to the use of adjuvant temozolomide. Inter-
estingly, immunotherapy with the angiogenesis inhibitor bevacizumab was also frequently
administered. However, two large prospective randomized trials recently revealed that bevaci-
zumab has no impact on the survival of GB patients [26, 27].
Limitations inherent to systematic reviews
First of all, there is certainly a selection bias, because the cases reported in the literature might
have been published due to their rare or uncommon occurrences and outcomes. Furthermore,
not all data were available for each individual patient, so that the time course of these diseases
could not always be reconstructed accurately. This is reflected by different patient numbers in
patient characteristics and survival analyses.
Statistical limitations. In this study, the potential benefit of radio- and/or chemotherapy
or other treatment-related factors for survival was not investigated. The reason for this is that
the patients in our cohort received individualized treatments to the effect that these factors
were unknown at the beginning of survival time. To investigate a variable that is still elusive at
the beginning of survival time or that changes over time, time-dependent Cox regression could
be used. Therefore this procedure requires particularly detailed information about the starting
date of therapy [28], which was generally not provided by these case reports in the literature.
Alternatively, the effect of a time-varying treatment could be investigated using marginal struc-
tural models or structural nested failure time models.
Conclusions
These rare tumors of the spinal cord are associated with a dismal prognosis whereby only mod-
est treatment progress has been achieved over the last decades. The characteristics and treat-
ments of primary spinal glioblastomas should be entered into a central registry in order to gain
more information about the ideal treatment approach in the future.
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